Combination Strategy to Attack Multiple Sclerosis


Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that's worked in treating HIV, cancer and heart failure -- combining medicines to increase their potency. The company has begun late-stage testing for its experimental medicine, ponesimod, which may work for people suffering from the most common type of multiple sclerosis, which affects roughly 85 percent of those diagnosed with the hard-to-detect and incurable disease.



from Biotech News